Moderated by Max Hotopf, CEO, Healthcare Business International
Panel examining B2C, genetics and impact of AI/big data on the lab sector
The B2C lab test market in Europe
Will Stoddard, CEO, Werlabs
There is a lot of pent up demand from consumers for tests. Who better to talk about this than Will whose business offers B2C tests across Scandinavia and the UK. Who are the typical customer? How do they behave? And what are the best ways of reaching them?
The genetic test market: A candid view
Enrique Samper CEO, Nimgenetics
Nimgenetics is one of the largest Spanish genetic labs and is selling across the Latino world. Here Enrique gives his personal view of the future of genetics. What price will tests need to hit before becoming mass B2B and B2C markets? What are the implications of 4P Medicine? And how can the sector deal with the huge challenges it faces around IP, educating the medical profession and staff shortages? Where will for-profit labs play in this?
Developing healthcare economies: The opportunity in diagnostics
Stuart Quin, Head of Central and Eastern Europe, Middle East and Africa, SYNLAB
Europe's largest lab group, SYNLAB, has expanded into a dozen markets from Mexico to Ukraine and Ghana to Slovakia. Why and what opportunities does it see? Stuart looks at the group's strategy and at how it adds value through innovation.
Contrasts between Europe and Emerging Market labs
Anoop Singh, General Manager, Healthscope Pathology International
Healthscope runs labs across Australia and New Zealand as well as across Malaysia, Vietnam and Singapore. Anoop who is also a non-exec director of Dr Lal, the big Indian lab group, contrasts business models.